Riborn Bio-B (06938.HK): Core Product Vortosiran Submits Phase 2b Clinical Trial Application for Venous Thromboembolism

NewTimeSpace News: Suzhou Riborn Biotech Co., Ltd. (06938.HK) released a voluntary announcement on May 11, 2026, stating that its core product vortosiran (RBD4059) has submitted a Phase 2b CTA to the EMA for the prevention and treatment of VTE. This study is part of the Company’s planned Phase 2b program covering multiple thromboembolic cardiovascular indications.

VTE remains a leading cause of morbidity and mortality in cardiovascular patients, affecting approximately 10 million people worldwide each year. A significant proportion of patients do not receive adequate treatment or even discontinue therapy due to the bleeding risk associated with current anticoagulants.

Vortosiran is a small interfering RNA (siRNA) drug for thrombotic diseases. It is designed to selectively and durably inhibit Coagulation Factor XI (FXI), block the FXI-mediated coagulation pathway, and suppress FXI coagulation activity.

This mechanism achieves strong thromboembolic protection while significantly reducing bleeding risk.

Vortosiran is the world’s most advanced small nucleic acid drug targeting FXI. As of the date of this announcement, the product has completed a Phase 2a clinical trial in Europe for coronary artery disease (CAD), and its Phase 2b CTA for atrial fibrillation (AF) was submitted to the EMA in April 2026.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.